Biothera Initiates Phase Ib/IIa Clinical Trial With Imprime PGG and Erbitux in Metastatic Colorectal Cancer Patients
Posted on: Tuesday, 9 October 2007, 12:00 CDT
Biothera announced today that it has initiated enrollment of patients in a phase Ib/IIa clinical trial to evaluate the safety and efficacy of Imprime PGG™ and Erbitux® in patients with metastatic colorectal cancer.
Imprime PGG is a unique biological response modifier that enhances specific innate immune cell responses without inducing pro-inflammatory cytokines. Erbitux (cetuximab) is a monoclonal antibody from ImClone Systems that is approved for treatment of colorectal and head and neck cancer.
Numerous xenograft mouse models have demonstrated that combining Imprime PGG and Erbitux or other anti-tumor monoclonal antibodies, including Avastin® (bevacizumab), and Herceptin® (trastuzumab), significantly reduces tumor size and increases survival compared with antibody therapy alone.
The phase Ib/IIa clinical trial is an open-label, multicenter trial in Asia. The goals of the trial are to assess the safety and efficacy of various Imprime PGG dose levels in metastatic colorectal cancer. The company is planning to follow the study with a double-blind, placebo-controlled Phase IIb trial in a larger patient population.
"This is the first of many trials that combine Imprime PGG and various monoclonal antibodies," said Daniel K. Conners, Biothera founder and chairman. "Imprime PGG engages an entirely new cancer killing mechanism that complements ADCC and CDC and which may improve the effectiveness of the majority of anti-tumor monoclonal antibodies on the market or in development."
Imprime PGG has demonstrated a strong safety profile in three clinical trials. Two Phase I clinical trials were conducted under Biothera's cancer Investigational New Drug (IND) application for the use of Imprime PGG in combination with anti-cancer monoclonal antibodies. Under a separate IND, the company also has completed a Phase I/II trial with Imprime PGG in combination with a hematopoietic growth factor.
About Biothera, the Immune Health Company
Biothera is a biotechnology company dedicated to improving immune health. The company's primary focus is developing pharmaceuticals that engage the innate immune system to fight cancer. Other applications include hematopoietic (white blood cell) recovery and infectious disease. Website: www.biotherapharma.com.
Source: Business Wire
Related Articles
- REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
- Hollis-Eden Pharmaceuticals Announces Filing of IND With APOPTONE(TM) in Hormone Sensitive Cancers to Commence Phase I/II Clinical Trial in Late-Stage Prostate Cancer
- Northwest Biotherapeutics Initiates Phase I/II Ovarian Cancer Trial
- Generex Biotechnology Announces Treatment of First Breast Cancer Patients in Phase II Clinical Trial
- ADVENTRX Receives FDA Clearance Under a Special Protocol Assessment to Initiate CoFactor Phase III Clinical Trial
- Cytokinetics Announces the Initiation of Phase I/II Clinical Trial for SB-743921
- Oxigene Plans Phase II Lung Cancer Trial
- Kosan Initiates Phase II Clinical Trial of KOS-953 in Combination With Herceptin(R) for Treatment of Metastatic Breast Cancer
- Bioaccelerate's Development Partner AustCancer Commences Phase II Clinical Study of RP101 for Metastatic Pancreatic Cancer
- AustCancer Commences Phase II Clinical Study of RP101 for Metastatic Pancreatic Cancer
 |
 |
User Comments (0)
RSS Feeds